Drug 2 autoimmune disease companion diagnostic - Sengenics
Alternative Names: Autoimmune Disease Drug 2 companion diagnostic - SengenicsLatest Information Update: 28 Aug 2022
At a glance
- Originator Sengenics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for clinical-Phase-Unknown development in Autoimmune-disorders(Diagnosis) in Singapore
- 25 Jul 2019 Clinical trials in Autoimmune disorders (Diagnosis) in Singapore (unspecified route) before July 2019
- 12 Jul 2019 Sengenics and the Foundation for the National Institutes of Health collaborate to develop diagnostics, companion diagnostics and therapeutics for Cancer, Autoimmune diseases and Neurodegenerative disorders